| http://www.w3.org/ns/prov#value | - Sarepta said it will proceed on the basis of a guidance letter from the FDA. The agency concluded that ???with additional data to support the efficacy and safety of eteplirsen for the treatment of DMD, an NDA should be fileable.??? The letter also outlined examples of additional data and analysis that it said will, if positive, enhance the acceptability of an NDA filing by addressing areas of ongo
|
